West Pharmaceutical Raises 2026 Sales Forecast
The Exton, Pennsylvania drug packaging company lifted its full-year revenue and earnings outlook after a strong third quarter.
Updated on Nov. 6, 2026 in Corporate Finance
West Pharmaceutical Services raised its full-year 2026 sales and earnings forecasts after reporting third-quarter net sales of $874.5 million, up 8.7% from a year earlier. Diluted earnings rose 57.3% to $3.02 per share.
Why it matters
The revised outlook reflects stronger performance in the Proprietary Products segment, particularly its high-value components business, which grew 19.7% in the quarter. The company also repurchased $231 million of its shares during the period.
Proprietary Products generated $728.8 million in quarterly revenue, while West Vantage revenue declined 7.3% to $145.7 million. West expects full-year organic revenue growth of 11.3% to 11.6%, though the filing does not explain the West Vantage decline.
The players
West Pharmaceutical Services
West Pharmaceutical Services is a Pennsylvania-based manufacturer of packaging and delivery components for injectable drugs, serving pharmaceutical and biotechnology companies.
The details
Diluted earnings rose to $3.02 per share in the third quarter, while adjusted diluted earnings increased 35.7% to $2.66 per share. High-Value Product Components sales climbed 19.7% to $466.7 million, and High-Value Product Delivery Devices generated $99.1 million in sales.
Timeline
Third quarter 2026: West reported net sales, earnings and share repurchases.
Oct. 19, 2026: Board declared a fourth-quarter dividend of 26 cents per share.
Market Landscape
West's raised guidance reflects continued demand for high-value injectable drug components within its Proprietary Products segment. The result positions the Exton-based supplier to grow faster than its more mature West Vantage business line.
Investors holding West shares received a raised full-year outlook and a 26-cent quarterly dividend declared on Oct. 19, 2026. The company's $231 million in third-quarter buybacks may affect shareholder returns going forward.
The takeaway
Rising high-value component sales drove West's improved outlook, while its shrinking West Vantage line bears watching. Investors may want to track whether the segment mix shift continues into next year's results.
Further reading
For more on company earnings and guidance changes, see Corporate Finance coverage across Pennsylvania.
Source note: This article includes information reported by MyChesCo.
